Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Waist-Hip Ratio
|
1138 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 2 | 2018 | 2019 | |||||
Triglycerides measurement
|
1418 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.800 | 1.000 | 5 | 2007 | 2018 | |||||
Systolic Pressure
|
1931 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 1 | 2016 | 2016 | |||||
Serum total cholesterol measurement
|
1243 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.800 | 1.000 | 8 | 2009 | 2018 | |||||
Serum LDL cholesterol measurement
|
555 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 10 | 2008 | 2013 | |||||
Serum HDL cholesterol measurement
|
679 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 2 | 2010 | 2013 | |||||
Rheumatoid Arthritis
|
2387 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.010 | 1.000 | 1 | 2013 | 2013 | |||||
Red cell distribution width determination
|
988 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 1 | 2017 | 2017 | |||||
RDW - Red blood cell distribution width result
|
988 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 1 | 2017 | 2017 | |||||
Psychomotor Performance
|
1 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 1 | 2012 | 2012 | |||||
Pseudocholinesterase Measurement
|
568 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 1 | 2011 | 2011 | |||||
Polycystic Ovary Syndrome
|
363 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.010 | 1 | 2018 | 2018 | ||||||
Obesity
|
1111 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.010 | 1.000 | 1 | 2015 | 2015 | |||||
Mental deterioration
|
121 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.710 | 1.000 | 2 | 2012 | 2019 | |||||
Memory performance
|
71 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 1 | 2015 | 2015 | |||||
Malignant Neoplasms
|
1641 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 1 | 2016 | 2016 | |||||
Low density lipoprotein cholesterol measurement
|
1142 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.800 | 1.000 | 16 | 2007 | 2019 | |||||
Longevity
|
74 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.800 | 1.000 | 2 | 2011 | 2014 | |||||
Impaired cognition
|
348 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
High density lipoprotein measurement
|
1440 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.800 | 1.000 | 7 | 2010 | 2019 | |||||
Hematocrit procedure
|
216 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 1 | 2016 | 2016 | |||||
Heart failure
|
201 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 1 | 2016 | 2016 | |||||
Glucose measurement
|
111 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 1 | 2016 | 2016 | |||||
Finding of body mass index
|
252 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 1 | 2015 | 2015 | |||||
elevated blood glucose level
|
111 | 0.708 | 0.520 | 19 | 44919689 | downstream gene variant | A/G | snv | 0.18 | 0.700 | 1.000 | 1 | 2016 | 2016 |